BSR statement on the NICE Document on Abatacept for rheumatoid arthritis

BSR statement on the NICE Appraisal Consultation Document on the use of Abatacept for the treatment of rheumatoid arthritis

The British Society for Rheumatology (BSR) is disappointed by the National Institute of Clinical Excellence (NICE) appraisal committee’s preliminary recommendation not to recommend abatacept for the treatment of people with rheumatoid arthritis.

We believe there is good evidence from clinical trials to support the use of abatacept in the treatment of rheumatoid arthritis, as an agent that effectively suppresses disease activity, increases function and improves health-related quality of life.

Dr Chris Deighton, Chair of the BSR Clinical Affairs Committee said; "Although the management of rheumatoid arthritis has improved substantially over recent years, there are still patients whose disease is resistant to current drugs. Clinicians need more treatment choices for patients with this aggressive disease."

The BSR will be submitting further evidence in support of the use of abatacept in our response to the recommendations.

For further information contact:
Katy Lewis
klewis@rheumatology.org.uk
(020) 7842 0919

August 2007